MOTS-c Peptide Protects Cartilage in Osteoarthritis by Boosting Mitochondria
Background
Osteoarthritis (OA) is a debilitating joint disease characterized by progressive cartilage degradation and chronic inflammation. Mitochondrial dysfunction and a specific inflammatory cell death called pyroptosis are increasingly recognized as key drivers of OA progression. Current treatments primarily manage symptoms, highlighting an urgent need for therapies that can address the underlying cellular pathology and prevent cartilage loss.
Why It Matters
This research highlights MOTS-c as a promising therapeutic candidate for osteoarthritis, offering a novel approach by simultaneously targeting mitochondrial health, reducing inflammatory cell death, and activating protective antioxidant pathways. The ability of MOTS-c to mitigate cartilage degradation suggests its potential to slow or even halt OA progression, moving beyond symptomatic relief. Future steps should include further preclinical optimization and eventually, Phase I/II human clinical trials to assess safety and efficacy.